• Aspire Biopharma clarified terms of its public warrants (ASPBW) following two reverse stock splits.
• Exercise price reset to $13,800 per share.
• Warrant ratio adjusted to 1,200 warrants for one common share.
• Changes reflect a 1-for-30 reverse split on Jan. 16, 2026, followed by a 40-for-1 reverse split on May 11, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033942), on July 20, 2026, and is solely responsible for the information contained therein.